Pipeline

Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Candidate
(genetic
medicine)
 
Indications
Discovery
IND Enabling
Phase 1
Phase 2
Phase 2
Systemically Administered (RedTail) Delivered
CLD-401
(IL-15 SA)
  • Multiple solid tumors
 
CLD-401(IL-15 SA)
Tumor-tropic genetic medicine that selectively lyses tumor cells, induces immune priming and transforms tumor cells into IL-15 superagonist (SA) producers for precise activation of anti-tumor immunity.
CLD-501
(undisclosed)
  • Myeloma, autoimmune
 
CLD-501 (Undisclosed)
Precision targeting to myeloma and B-cells. Expresses an immunomodulatory genetic medicine payload.
CLD-601
(undisclosed)
  • Oncology (undisclosed)
 
CLD-601 (Undisclosed)
Precision targeting to tumor cells (undisclosed target). Induces tumor lysis, immune priming, and expresses multiple payloads to precisely retarget T-cell activity against tumor cells.
Intratumorally Delivered
NeuroNova
  • Rel/ref glioblastoma
 
NeuroNova
Oncolytic virus loaded into stem cells for enhanced potency and immune evasion. Optimized for localized administration.
SuperNova
  • TNBC, SCCHN, sarcoma
 
SuperNova
Oncolytic virus loaded into stem cells for enhanced potency and immune evasion for solid tumors. Optimized for intratumoral administration. Calidi Biotherapeutics does not currently have an expanded access program for our investigational product Supernova. Participation in our clinical trial is the only way to access Supernova at this time.
Systemically Administered (RedTail) Delivered

CLD-401 (IL-15 SA)
Tumor-tropic genetic medicine that selectively lyses tumor cells, induces immune priming and transforms tumor cells into IL-15 superagonist (SA) producers for precise activation of anti-tumor immunity.

Indications
Stage
Multiple solid tumors
IND Enabling40%
40%

CLD-501 (Undisclosed)
Precision targeting to myeloma and B-cells. Expresses an immunomodulatory genetic medicine payload.

Indications
Stage
Myeloma, autoimmune
Discovery20%
20%

CLD-601 (Undisclosed)
Precision targeting to tumor cells (undisclosed target). Induces tumor lysis, immune priming, and expresses multiple payloads to precisely retarget T-cell activity against tumor cells.

Indications
Stage
Oncology (undisclosed)
Discovery20%
20%
Intratumorally Delivered

NeuroNova
Oncolytic virus loaded into stem cells for enhanced potency and immune evasion. Optimized for localized administration.

Indications
Stage
Rel/Ref glioblastoma
Phase 280%
80%

SuperNova
Oncolytic virus loaded into stem cells for enhanced potency and immune evasion for solid tumors. Optimized for intratumoral administration. Calidi Biotherapeutics does not currently have an expanded access program for our investigational product Supernova. Participation in our clinical trial is the only way to access Supernova at this time.

Indications
Stage
TNBC, SCCHN, Scarcoma
Phase 160%
60%

Press Releases

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Read More